Lv4
550 积分 2020-11-17 加入
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
7个月前
已关闭
Complexities of glucuronidation affecting in vitro in vivo extrapolation
7个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
9个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
10个月前
已完结
New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads
1年前
已完结
皖公网安备34019202002308
